Regenxbio (RGNX) Stock Rating Reaffirmed by Chardan Capital

Regenxbio (NASDAQ:RGNX)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a note issued to investors on Monday. They currently have a $127.50 target price on the biotechnology company’s stock. Chardan Capital’s price target points to a potential upside of 174.31% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. Raymond James set a $96.00 price objective on shares of Regenxbio and gave the stock a “buy” rating in a research note on Thursday, November 8th. Zacks Investment Research upgraded shares of Regenxbio from a “hold” rating to a “buy” rating and set a $78.00 price objective for the company in a research note on Wednesday, November 7th. BidaskClub upgraded shares of Regenxbio from a “hold” rating to a “buy” rating in a research note on Saturday, November 3rd. ValuEngine downgraded shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Finally, TheStreet upgraded shares of Regenxbio from a “d+” rating to a “c” rating in a research note on Monday, September 17th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $78.44.

RGNX opened at $46.48 on Monday. Regenxbio has a 52-week low of $23.25 and a 52-week high of $85.10. The company has a market cap of $1.64 billion, a price-to-earnings ratio of -18.97, a price-to-earnings-growth ratio of 6.74 and a beta of -0.52.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.30. Regenxbio had a net margin of 44.30% and a return on equity of 22.52%. The company had revenue of $5.31 million during the quarter. As a group, sell-side analysts predict that Regenxbio will post 2.23 EPS for the current year.

In other news, SVP Patrick J. Christmas sold 5,000 shares of the company’s stock in a transaction on Thursday, October 18th. The shares were sold at an average price of $61.78, for a total value of $308,900.00. Following the completion of the transaction, the senior vice president now directly owns 22,669 shares in the company, valued at $1,400,490.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kenneth T. Mills sold 7,510 shares of the company’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $59.35, for a total transaction of $445,718.50. Following the completion of the transaction, the chief executive officer now owns 331,710 shares of the company’s stock, valued at $19,686,988.50. The disclosure for this sale can be found here. Insiders sold 433,944 shares of company stock valued at $27,778,892 over the last 90 days. Insiders own 16.90% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Regenxbio by 12.1% in the third quarter. BlackRock Inc. now owns 4,727,045 shares of the biotechnology company’s stock valued at $356,893,000 after acquiring an additional 508,632 shares in the last quarter. Vanguard Group Inc raised its holdings in Regenxbio by 51.0% in the third quarter. Vanguard Group Inc now owns 2,805,969 shares of the biotechnology company’s stock valued at $211,851,000 after acquiring an additional 947,671 shares in the last quarter. Vanguard Group Inc. raised its holdings in Regenxbio by 51.0% in the third quarter. Vanguard Group Inc. now owns 2,805,969 shares of the biotechnology company’s stock valued at $211,851,000 after acquiring an additional 947,671 shares in the last quarter. RTW Investments LP raised its holdings in Regenxbio by 10.7% in the second quarter. RTW Investments LP now owns 2,079,555 shares of the biotechnology company’s stock valued at $149,208,000 after acquiring an additional 201,788 shares in the last quarter. Finally, Redmile Group LLC raised its holdings in Regenxbio by 6.1% in the third quarter. Redmile Group LLC now owns 1,656,065 shares of the biotechnology company’s stock valued at $125,033,000 after acquiring an additional 94,890 shares in the last quarter. 79.06% of the stock is currently owned by hedge funds and other institutional investors.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Read More: How do investors use RSI to grade stocks?

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply